FDA Approvals Roundup: Camzyos, Vivjoa, Epsolay

Bristol Myers Squibb’s Camzyos (mavacamten; capsules) has been approved for treating adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.